日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study

伊姆鲁司群(一种口服选择性雌激素受体降解剂)联合HER2靶向治疗,无论是否联合阿贝西利,用于治疗ER阳性、HER2阳性晚期乳腺癌:来自EMBER 1a/1b期研究的结果

Bhave, Manali; Jhaveri, Komal L; Kaufman, Peter A; Aftimos, Philippe; Lombard, Janine; Giridhar, Karthik V; Im, Seock-Ah; Ma, Cynthia X; Lee, Kuo-Ting; Kim, Sung-Bae; Sohn, Joohyuk; Li, Yujia; Yuen, Eunice; Estrem, Shawn T; Nguyen, Bastien; Makena, Monish Ram; Ismail-Khan, Roohi; Beeram, Muralidhar

Survival benefit from abemaciclib in non-small cell lung cancer by Kirsten rat sarcoma-mutation gene expression subtype: retrospective analysis from the JUNIPER Trial

根据 Kirsten 大鼠肉瘤突变基因表达亚型分析阿贝西利治疗非小细胞肺癌的生存获益:JUNIPER 试验的回顾性分析

Liu, Jiangang; Wang, Hong; Aggarwal, Amit; Ortiz-Ruiz, Maria Jesus; Zapatero-Solana, Elisabet; Lallena, Maria Jose; Peregrina, Sandra; Del Hoyo, Gloria Martinez; Velasco, Susana; Ebert, Philip J; Gong, Xueqian; Hossain, Anwar M; Estrem, Shawn T

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study

伊姆伦司群(一种口服选择性雌激素受体降解剂)单药治疗及联合靶向治疗在雌激素受体阳性、人表皮生长因子受体2阴性晚期乳腺癌中的疗效:EMBER Ia/Ib期研究

Jhaveri, Komal L; Lim, Elgene; Jeselsohn, Rinath; Ma, Cynthia X; Hamilton, Erika P; Osborne, Cynthia; Bhave, Manali; Kaufman, Peter A; Beck, J Thaddeus; Manso Sanchez, Luis; Parajuli, Ritesh; Wang, Hwei-Chung; Tao, Jessica J; Im, Seock-Ah; Harnden, Kathleen; Yonemori, Kan; Dhakal, Ajay; Neven, Patrick; Aftimos, Philippe; Pierga, Jean-Yves; Lu, Yen-Shen; Larson, Timothy; Jerez, Yolanda; Sideras, Kostandinos; Sohn, Joohyuk; Kim, Sung-Bae; Saura, Cristina; Bardia, Aditya; Sammons, Sarah L; Bacchion, Francesca; Li, Yujia; Yuen, Eunice; Estrem, Shawn T; Rodrik-Outmezguine, Vanessa; Nguyen, Bastien; Ismail-Khan, Roohi; Smyth, Lillian; Beeram, Muralidhar

A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study

一项针对新诊断的ER阳性、HER2阴性早期乳腺癌患者的术前机会窗口研究:口服选择性雌激素受体拮抗剂(SERD)伊姆伦司群的疗效:EMBER-2研究结果

Neven, Patrick; Stahl, Nicole; Vidal, Maria; Martín, Miguel; Kaufman, Peter A; Harbeck, Nadia; Hunt, Kelly K; Carter, Stacey; Bidard, Francois-Clement; Fasching, Peter A; Aftimos, Philippe; Wheatley, Duncan; Hamilton, Erika; Aft, Rebecca; Kulkarni, Swati; Schmid, Peter; Bhave, Manali; Ismail-Khan, Roohi; Karacsonyi, Claudia; Estrem, Shawn T; Nguyen, Bastien; Ozbek, Umut; Yuen, Eunice; Rodrik-Outmezguine, Vanessa; Ciruelos, Eva

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer

一项针对实体瘤和非小细胞肺癌的 galunisertib 联合 nivolumab 的 Ib/II 期研究

Nadal, Ernest; Saleh, Mansoor; Aix, Santiago Ponce; Ochoa-de-Olza, Maria; Patel, Sandip Pravin; Antonia, Scott; Zhao, Yumin; Gueorguieva, Ivelina; Man, Michael; Estrem, Shawn T; Liu, Jiangang; Avsar, Emin; Lin, Wen Hong; Benhadji, Karim A; Gandhi, Leena; Guba, Susan C; Diaz, Inmaculada Ales

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

TGFβ受体I激酶抑制剂galunisertib联合抗PD-L1抗体durvalumab治疗转移性胰腺癌的安全性和活性

Melisi, Davide; Oh, Do-Youn; Hollebecque, Antoine; Calvo, Emiliano; Varghese, Anna; Borazanci, Erkut; Macarulla, Teresa; Merz, Valeria; Zecchetto, Camilla; Zhao, Yumin; Gueorguieva, Ivelina; Man, Michael; Gandhi, Leena; Estrem, Shawn T; Benhadji, Karim A; Lanasa, Mark C; Avsar, Emin; Guba, Susan C; Garcia-Carbonero, Rocio

First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

针对晚期癌症患者的下一代口服TGFβ受体1抑制剂LY3200882的首次人体I期研究

Yap, Timothy A; Vieito, Maria; Baldini, Capucine; Sepúlveda-Sánchez, Juan Manuel; Kondo, Shunsuke; Simonelli, Matteo; Cosman, Rasha; van der Westhuizen, Andre; Atkinson, Victoria; Carpentier, Antoine F; Löhr, Mario; Redman, Rebecca; Mason, Warren; Cervantes, Andres; Le Rhun, Emilie; Ochsenreither, Sebastian; Warren, Louise; Zhao, Yumin; Callies, Sophie; Estrem, Shawn T; Man, Michael; Gandhi, Leena; Avsar, Emin; Melisi, Davide

A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER

一项随机III期研究,比较阿贝西利与厄洛替尼治疗既往铂类化疗失败且携带可检测KRAS突变的IV期非小细胞肺癌患者的疗效:JUNIPER

Goldman, Jonathan W; Mazieres, Julien; Barlesi, Fabrice; Dragnev, Konstantin H; Koczywas, Marianna; Göskel, Tuncay; Cortot, Alexis B; Girard, Nicolas; Wesseler, Claas; Bischoff, Helge; Nadal, Ernest; Park, Keunchil; Lu, Shun; Taus, Alvaro; Cobo, Manuel; Estrem, Shawn T; Wijayawardana, Sameera R; Turner, Kellie; Oakley, Gerard Joseph 3rd; Hurt, Karla C; Chiang, Alan Y; Hossain, Anwar M; John, William J; Paz-Ares, Luis

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma

一项针对新诊断恶性胶质瘤患者的 1b/2a 期研究,评估了转化生长因子-β受体I小分子抑制剂 galunisertib 与基于替莫唑胺的标准放化疗方案联合治疗的疗效。

Wick, Antje; Desjardins, Annick; Suarez, Cristina; Forsyth, Peter; Gueorguieva, Ivelina; Burkholder, Tiana; Cleverly, Ann Louise; Estrem, Shawn T; Wang, Shuaicheng; Lahn, Michael M; Guba, Susan C; Capper, David; Rodon, Jordi

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

Galunisertib联合吉西他滨对比吉西他滨单药治疗不可切除胰腺癌患者的一线疗效

Melisi, Davide; Garcia-Carbonero, Rocio; Macarulla, Teresa; Pezet, Denis; Deplanque, Gael; Fuchs, Martin; Trojan, Jorg; Oettle, Helmut; Kozloff, Mark; Cleverly, Ann; Smith, Claire; Estrem, Shawn T; Gueorguieva, Ivelina; Lahn, Michael M F; Blunt, Al; Benhadji, Karim A; Tabernero, Josep